FitLife Brands, Inc. - Common Stock (FTLF)
Healthcare › Medicinal Chemicals & Botanical Products
Price History
Feb 9, 2026 — Mar 28, 2026Investment Snapshot
- Trading 67% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 16.3% — good return on equity
FitLife Brands, Inc. - Common Stock (FTLF) is a Healthcare company operating in Medicinal Chemicals & Botanical Products, listed on the NASDAQ , with a market capitalisation of $134 million . Key value metrics: P/E ratio 19.7, P/B ratio 3.20, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
FitLife Brands, Inc. - Common Stock — Fundamental Analysis Summary
FitLife Brands, Inc. - Common Stock (FTLF) is currently trading 67% above its Graham Number of $8.53, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 19.7x.
On financial health, FTLF shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and solid return on equity of 16.3% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.11.
StockPik's composite Value Score for FTLF is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
FTLF reports a solid gross margin of 43.2% (sector average: 33.5%) and a solid operating margin of 19.3%.
FTLF shows earnings growing at 70%.